Ingenuity Expands Scope of Licensing Agreement with Sanofi-Aventis
News Mar 08, 2006
Ingenuity Pathways Analysis is a web-delivered software application that is designed to enable researchers to model, analyze and understand the complex biological systems at the core of life science research.
Ingenuity Pathways Analysis supports analysis of high throughput analysis platforms and is used in virtually all areas of drug discovery and development from target identification and validation to biomarkers, predictive toxicology, and pharmacogenomics.
"Sanofi-aventis was one of the earliest adopters of Ingenuity technology and we are very pleased that we have been able to expand our relationship with this terrific team year after year," stated Peter DiLaura, Vice President, Sales and Customer Support.
"The Ingenuity product line enables IPA users to understand complex biology within their research, in addition to supporting the Bioinformatics team to further develop robust and proprietary computational solutions."
Ingenuity Pathways Analysis is available as a web-delivered, hosted, or deployed solution. Fully functional complimentary trials are available online.
Single Gene Change in Gut Bacteria Alters Host MetabolismNews
Scientists have found that deleting a single gene in a particular strain of gut bacteria causes changes in metabolism and reduced weight gain in mice. The research provides an important step towards understanding how the microbiome – the bacteria that live in our body – affects metabolism.READ MORE
Gotta Sample 'Em All! Underwater Pokéball Captures Ocean LifeNews
A new device developed by Wyss Institute reseachers safely traps delicate sea creatures inside a folding polyhedral enclosure and lets them go without harm using a novel, origami-inspired design. The ultimate aim is to allow the sea creatures to be (gently) analyzed in high detail.READ MORE
CRISPR Screening Reveals Sickle Cell Disease TargetNews
A key signaling protein, known as heme-regulated inhibitor (HRI), has been identified as a potential therapeutic target for the development of drugs to treat sickle cell disease, using a CRISPR screening approach.READ MORE
International Conference on Neurooncology and Neurosurgery
Sep 17 - Sep 18, 2018